Medical experts discuss the unmet needs surrounding homozygous FH. Eliot Brinton, MD: With all the tools we have for homozygous familial hypercholesterolemia [HoFH], there are patients who spend way ...
For years, father of two Peter Martini experienced subtle symptoms that never seemed serious enough to raise alarm, but in ...
Seth Baum, MD, and Erin Michos, MD, MHS, discuss pediatric diagnosis of homozygous FH. Erin Michos, MD, MHS: It’s so important that patients with [HoFH] get diagnosed early in childhood. You know, as ...
Do you know your LDL? It's the bad cholesterol in our bodies and the American Heart Association says keeping it under 100 is best to avoid heart attacks and strokes, but for some people no matter what ...
LIBerate-HoFH study was part of a global registration-enabling Phase 3 program of > 2,900 patients Biologics license application for lerodalcibep submitted to FDA in December 2024 ...
MANNHEIM, Germany—Response to treatment is highly variable with the investigational PCSK9 inhibitor lerodalcibep (LIB Therapeutics), as well as with evolocumab (Repatha; Amgen), in patients who have ...
NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence (NICE) has issued a final ...
Please provide your email address to receive an email when new articles are posted on . Regeneron Pharmaceuticals announced the FDA has extended approval of evinacumab-dgnb as an adjunct to other ...
HoFH is a rare genetic condition that leads to extremely high levels of low-density lipoprotein cholesterol (LDL). Credit: Kitsawet Saethao/Shutterstock. · Clinical Trials Arena · Kitsawet ...
London, UK - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that the lomitapide preparation Lojuxta (Aegerion Pharmaceuticals) be ...
The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH. The Food and Drug Administration (FDA) has approved Repatha (evolocumab) injection as an adjunct to ...
Regeneron Pharmaceuticals, Inc.REGN presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results